Target- |
MechanismProthrombin replacements |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date18 Feb 2022 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date21 Jan 2020 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date01 Jan 1995 |
100 Clinical Results associated with Changchun Leiyunshang Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Changchun Leiyunshang Pharmaceutical Co., Ltd.
100 Deals associated with Changchun Leiyunshang Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Changchun Leiyunshang Pharmaceutical Co., Ltd.